Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2013

View Archived Issues

Novel macrocycles for diabetes discovered at Harvard College

New anti-ICAM-1 MAbs developed in Korea

FAK inhibitors described at Merck & Co.

Roche issues overview of 2012 activities

AbbVie provides overview of 2012, looks ahead to 2013

VG Life Sciences reports results from sorafenib combination trial

Vitamin D deficiency linked to sepsis risk and outcomes

Hypertension treatment nebivolol investigated in Alzheimer's disease model

Combined viral vaccines developed at Novartis

Tricyclic pim kinase inhibitors reported by the Spanish CNIO

Relaxin fusion polypeptides developed at Bayer

MAbs to CCR6 developed at Kyowa Hakko Kirin

New genetic variants identified linked to autism spectrum disorders

AC Immune to discontinue development of ACI-91

Teva Pharmaceutical terminates agreements with CureTech

Phase II study under way for Cerulean's CRLX-101 in relapsed SCLC

Merck & Co. submits BLA for grass allergy immunotherapy tablet

Novel compounds described as potential therapies for nerve agent poisoning

BTG submits Varisolve NDA

Vernalis' drug discovery collaboration with Genentech yields milestone payment

FDA approves Ravicti for urea cycle disorders

Wellcome Trust award supports phase I/II trial of Newron's sNN-0029

Health Canada grants approval to Adcetris for two lymphoma indications

Alchemia reaches original enrollment target in phase III study of HA-irinotecan

Lyxumia approved in E.U. as first once-daily prandial GLP-1 receptor agonist

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...